Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 2025
Cet article présente les recommandations d'un groupe d'experts international sur la prise en charge des cancers à cellules rénales et des cancers des voies urinaires
Treatment advances in renal cell carcinoma (RCC) and urothelial carcinoma (UC) have redefined patient outcomes within a single decade, transforming fatal diseases into chronic, manageable conditions for many. The widespread adoption of multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and the antibody–drug conjugate enfortumab vedotin (EV) has extended survival compared with historic standards. Yet this progress has introduced new complexity, including overlapping mechanisms, inconsistent success across trials, and limited generalizability because of narrow eligibility criteria along with the lack of reliable predictive biomarkers.
CA: A Cancer Journal for Clinicians , éditorial en libre accès, 2025